| INSTRUCTIONS FOR USE
GB
PRESSURE-FLOW CHARACTERISTICS
The following diagrams show the pressure-flow characteristics for the available pressure settings of
the GAV 2.0 (Fig. 7). The total opening pressure refers to a reference flow of 5 ml/h. For flow rates
of 20 ml/h, stated pressures are approx. 1-2 cmH
GAV 2.0: 5/20
55
50
45
40
35
30
25
Vertical Position
20
15
10
Horizontal Position
5
0
5
10
15
20
25
30
35
40
45
50
55
a)
Flow Rate (ml/h)
GAV 2.0: 5/25
55
50
45
40
35
30
Vertical Position
25
20
15
10
Horizontal Position
5
0
5
10
15
20
25
30
35
40
45
50
55
b)
Flow Rate (ml/h)
GAV 2.0: 5/30
55
50
45
40
35
Vertical Position
30
25
20
15
10
Horizontal Position
5
0
5
10
15
20
25
30
35
40
45
50
55
c)
Flow Rate (ml/h)
Fig. 7: Pressure-flow characteristics for the available pressure settings of the GAV 2.0
16
GAV 2.0
O higher.
2
GAV 2.0: 5/35
55
50
45
40
Vertical Position
35
30
25
20
15
10
Horizontal Position
5
0
5
10
15
20
25
30
35
40
45
50
55
GAV 2.0: 10/25
55
50
45
40
35
30
Vertical Position
25
20
15
Horizontal Position
10
5
0
5
10
15
20
25
30
35
40
45
50
55
e)
Flow Rate (ml/h)
GAV 2.0: 10/30
55
50
45
40
35
Vertical Position
30
25
20
15
Horizontal Position
10
5
0
5
10
15
20
25
30
35
40
45
50
55
f)
Flow Rate (ml/h)
GAV 2.0
PRECAUTIONS AND
CONTRAINDICATIONS
Patients must be carefully monitored after im-
plantation. Reddening of skin or tightness in the
area of the drained tissue may be indications of
infections at the shunt system. Symptoms such
as headache, dizziness, confusion or vomiting
often occur in conjunction with shunt dysfunc-
tion. These symptoms and a leakage within the
shunt system require the immediate replace-
ment of the affected shunt component or the
entire shunt system.
The implantation of medical devices is contra-
indicated if the patient has an infection or su-
spected infection (e.g. meningitis, ventriculitis,
peritonitis, bacteriaemia, septicaemia) in the
region affected by the implantation.
FUNCTIONAL SAFETY
AND COMPATIBILITY WITH
DIAGNOSTIC PROCEDURES
These medical devices are constructed in such
a way as to ensure their precise and reliable
operation over long periods of time. However,
no guarantee can be given that these medical
devices may not require replacement for me-
dical or technical reasons. These medical de-
vices are able to resist positive and negative
pressures up to 200 cmH
O during and after
2
implantation. These medical devices have to
be stored in a clean and dry environment at all
times.
Nuclear magnetic resonance examinations up
to a field strength of 3 Tesla or computed tomo-
graphy examinations can be performed without
risk or impairment to the valve function. The
valve is MR Conditional. Supplied catheters are
MR Safe. Reservoirs, deflectors and connec-
tors are MR Conditional.
INSTRUCTIONS FOR USE |
ADVERSE REACTIONS AND
INTERACTIONS
In the treatment of hydrocephalus with shunts,
the following complications may arise (as de-
scribed in the literature): infections, blockages
caused by protein and/or blood in the cerebro-
spinal fluid, over/under drainage or in very rare
cases noise development. Violent shocks for
the outside (accident, fall) may put the integrity
of the shunt system at risk.
The GAV 2.0 must not be used in conjunction
with hydrostatic valves as this may result in
increased ventricular pressure outside of the
physiological range. In case of doubt, please
contact the medical device consultants at Chri-
stoph Miethke GmbH & Co. KG.
STERILISATION
The products are sterilised with steam under
strictly controlled conditions. The double wrap-
ping in sterile bags ensures sterility for a five-
year period. The expiry date is printed on the
wrapping of each individual product. If the pa-
ckaging is damaged, the product must not be
used in any circumstances. No guarantee can
be given for the functional safety and reliability
of resterilised products.
REQUIREMENTS OF THE MDD
(DIRECTIVE 93/42/EEC)
The Medical Device Directive requires the com-
prehensive documentation of the whereabouts
of medical devices used in humans. The indivi-
dual identification number of the implanted val-
ve should therefore be recorded in the patient's
medical records and patient data card to ensu-
re complete traceability.
Translations of these instructions for use into
additional languages can be found on our web-
site
(https://www.miethke.com/en/products/
downloads/).
GB
17